Charts

25 Sep, 2022

News

14 Sep, 2022
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that its research collaborators from London’s Institute of Hepatology will present new findings on the Company’s cyclophilin inhibitor, renco
12 Sep, 2022
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ: MRSN) lead ...
- Hepion Collaborates with HepQuant and Summit Clinical Research to Evaluate Rencofilstat’s Impact on Hepatic Function and Numerous NASH Functional Biomarkers - - F3 NASH Subjects will be Evaluated on Three Doses of Rencofilstat for a Four-month Period - EDISON, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoho
09 Sep, 2022
Gainers Quotient (NASDAQ:QTNT) shares moved upwards by 18.1% to $0.21 during Friday's pre-market session. The market ...
08 Sep, 2022
EDISON, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference. Hepion’s pre-recorded presentation will be availabl
31 Aug, 2022
- Hepion Screens First Subject in Biopsy-Confirmed F2/F3 NASH Study - - Subjects will be Evaluated on Three Doses of Rencofilstat for a One-year Period - EDISON, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, toda
22 Aug, 2022
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market ...
01 Aug, 2022
On Monday, 92 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company ...
28 Jul, 2022
On Thursday, 108 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Vodafone Group ...
27 Jul, 2022
Wednesday saw 83 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Orange (NYSE:ORAN) ...
22 Jul, 2022
EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) has been further adjourned to Friday, August 5, 2022 at 9:00 a.m. Eastern Time with respect to Propos
04 Jul, 2022
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
28 Jun, 2022
EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the appointments of Anand Reddi, M.S., and Kaouthar Lbiati, M.D., to its Board of Directors, effective immediately. “We are thrilled to welcome individuals of this calib
24 Jun, 2022
EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its 2022 annual meeting of stockholders (the “Annual Meeting”) has been adjourned to Friday, July 22, 2022 at 9:00 a.m. Eastern Time with respect to Proposal 4 (Aut
21 Jun, 2022
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA AdComm Gives Thumbs Down ...
Gainers Valneva SE(NASDAQ: VALN) shares rose 83.6% to $25.18in pre-market trading following Pfizer agreement to ...
20 Jun, 2022
EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibit
15 Jun, 2022
- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced that five abstracts have been accepted for poster presenta
14 Jun, 2022
- Dr. Aspeslet joins the Company to support rencofilstat’s clinical program - EDISON, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the appointment of Launa J. Aspeslet, PhD, RAC, as Chief Operating Officer. A versatile C-level
31 May, 2022
EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today urged its stockholders to vote “FOR” all proposals put forth in the definitive proxy statement prior to its June 24, 2022 Annual Meeting of Stockholders. “As one equity analyst recentl
27 May, 2022
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been informed by the company that in both the headline and first paragraph the name 'Recofilstat' should be 'Rencofilstat'. Completed corrected text follows. Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Rencofilstat at 5th Global NASH Congress Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company fo
EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announces that its Chief Medical Officer, Todd Hobbs, MD, gave a clinical presentation entitled “Recofilstat (CRV431): A liver-targeting drug candidate for NASH and HCC” today at the 5th Glo
19 May, 2022
Gainers Radius Health (NASDAQ:RDUS) stock moved upwards by 18.8% to $6.94 during Thursday's after-market session. The company's ...
03 May, 2022
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - - Four-Month, Three Arm Trial will Inform on Numerous NASH Functional Biomarkers - EDISON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treat
07 Mar, 2022
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time. The virtual presentation will be broa
28 Feb, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth ...
15 Feb, 2022
- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in Asia - EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular c
14 Feb, 2022
EDISON, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, Feburary 15, 2022 at 11:15 a.m. Eastern Time at the New Y
26 Jan, 2022
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM) shares increased by 6.4% to $6.82 during Wednesday's after-market session. The company's ...
Hepion Pharmaceuticals Inc(NASDAQ: HEPA) has announced the results of a nonclinical research study showing rencofilstat ...
Anti-tumor activity observed in fatty livers suggests rencofilstat may increase the treatment potential of anti-PD1 treatment in human liver cancerEDISON, N.J., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), today announced the results of a nonclinic
24 Jan, 2022
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! It's time to get this week going with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...
12 Jan, 2022
EDISON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- It is with profound sadness that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the passing of Thomas Adams, Ph.D., a member of its Board of Directors. Dr. Adams died of natural causes on January 9, 2022. A seasoned biotechnology veteran, Dr. Adams was appointed to Hepion’s Board in September 2016. "We are deeply saddened by the loss of our dear friend and colleague,” said Hepion’s Chairman, Gary S. Jacob, Ph.D. “On behalf of the Company’s Bo
07 Jan, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug ...
29 Sep, 2021
Hepion Pharmaceuticals Inc(NASDAQ: HEPA) hasannounced results from a Drug-Drug Interaction (DDI) studywith its lead ...
15 Sep, 2021
Investors in Hepion Pharmaceuticals Inc (HEPA) saw new options become available this week, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 856 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
13 Sep, 2021
Hepion Pharmaceuticals Inc(NASDAQ: HEPA) has announced additional efficacy data from its Phase 2a AMBITION clinical ...
Gainers Itamar Medical (NASDAQ:ITMR) shares moved upwards by 44.37% to $29.8 during Monday's pre-market session. The ...
Gainers Itamar Medical Ltd. (NASDAQ: ITMR) rose 43% to $29.52 in pre-market trading. Zoll Medical said it has signed an agreement ...
Hepion Pharmaceuticals Inc(NASDAQ: HEPA) stock is moving higher during premarketahead of additional datafrom its ...
12 Sep, 2021
Biotech stocks retreated in the holiday-shortened week endingSept. 10, reversing course from the previous week. Humanigen, Inc. ...
10 Sep, 2021
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA) shares rose 10.84% to $1.84 during Friday's after-market session. Hepion ...
20 Aug, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
04 Aug, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
16 Jul, 2021
Investors in Hepion Pharmaceuticals Inc (HEPA) saw new options become available this week, for the March 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
14 Jul, 2021
08:50
FinancialContent
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday. Red Cat Holdings, ...
13 Jul, 2021
Hepion Pharmaceuticals Inc(NASDAQ: HEPA) hasannounced positive topline resultsfrom its Phase 2a AMBITION NASH ...
Gainers SCWorx (NASDAQ:WORX) stock increased by 38.34% to $3.68 during Tuesday's pre-market session. The ...
25 Jun, 2021
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're back at it again with another look at the biggest pre-market stock movers for Friday as the perfect way to close out the week. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner
21 May, 2021
Investors in Hepion Pharmaceuticals Inc (HEPA) saw new options become available this week, for the July 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the HEPA options chain for the new July 16th contracts and identified the following call contract of particular interest.
14 May, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
31 Mar, 2021
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher. The post 7 Penny Stocks That May Have Room to Run Higher appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now
26 Mar, 2021
It's curtains down on the virtual, two-day Benzinga Biotech Small Cap Conference, where C-suiteexecutives of top small-cap ...
23 Mar, 2021
Hepion Pharmaceuticals Inc(NASDAQ:HEPA) hasannounced positive resultsfrom anin vivostudy of ...
22 Mar, 2021
Hepion Pharmaceuticals (NASDAQ: HEPA) is one of the sponsors for the Benzinga Biotech Global Small Cap Conference taking place on March ...
19 Mar, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
16 Mar, 2021
10:29
FinancialContent
Gainers Sigma Labs, Inc. (NASDAQ: SGLB) jumped 128.7% to close at $7.64 on Monday after the company secured a contract for an ...
15 Mar, 2021
Gainers Rubius Therapeutics, Inc. (NASDAQ: RUBY) shares jumped 102.6% to $33.29 after the company reported initial clinical data ...
Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares rose 87.1% to $6.38 in pre-market trading. Acer Therapeutics, earlier during ...
19 Feb, 2021
Gainers Cuentas Inc. (NASDAQ: CUEN) shares rose 72.6% to $6.48 in pre-market trading. Cuentas, earlier during the month, priced ...
17 Feb, 2021
11:03
FinancialContent
Gainers Socket Mobile, Inc. (NASDAQ: SCKT) shares jumped 538.3% to close at $20.68 on Tuesday, driven by heavy volumes after the ...
16 Feb, 2021
Gainers Socket Mobile, Inc. (NASDAQ: SCKT) shares shot up 191.67% to $9.45, driven by heavy volumes after the company unveiled ...
10 Feb, 2021
25 Nov, 2020
05 Oct, 2020

Related Articles